Document Detail


Ximelagatran for prevention and treatment of venous thromboembolism.
MedLine Citation:
PMID:  15214359     Owner:  HSR     Status:  MEDLINE    
Abstract/OtherAbstract:
Ximelagatran (Exanta (TM)) is the first oral agent in a new class of anticoagulants called direct thrombin inhibitors. Most of the available evidence regarding venous thromboembolism is from studies focusing on its prevention after major orthopedic surgery. Ximelagatran's efficacy is comparable to that of warfarin and low-molecular-weight heparin in this setting. The rates of bleeding complications for ximelagatran and its comparators were not statistically different. The elevation of liver enzymes was observed in longer term trials.
Authors:
Lisa Kwok; Michel Boucher
Related Documents :
12521409 - Primary postpartum haemorrhage.
17486199 - Results of a program for the prevention of blindness caused by retinopathy of prematuri...
23223159 - Therapeutic hypothermia during neonatal transport: data from the california perinatal q...
9056049 - Prevention of amlodipine absorption by activated charcoal: effect of delay in charcoal ...
10941649 - Management of flap striae.
15539879 - In utero meconium suctioning may prevent meconium aspiration.
21158219 - Case series of neonatal hypocalcemia due to pseudohypoparathyroidism.
23659739 - Feeding choice has a gender-associated effect on infant growth.
8668389 - Use and abuse of the apgar score. committee on fetus and newborn, american academy of p...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Issues in emerging health technologies     Volume:  -     ISSN:  1488-6316     ISO Abbreviation:  Issues Emerg Health Technol     Publication Date:  2004 Jun 
Date Detail:
Created Date:  2004-06-23     Completed Date:  2004-07-07     Revised Date:  2010-01-22    
Medline Journal Info:
Nlm Unique ID:  100886782     Medline TA:  Issues Emerg Health Technol     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  1-4     Citation Subset:  T    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Anticoagulants / adverse effects,  pharmacology,  therapeutic use*
Azetidines / adverse effects,  pharmacology,  therapeutic use*
Canada
Clinical Trials as Topic
Dose-Response Relationship, Drug
Drug Approval
Europe
Evidence-Based Medicine
Heparin, Low-Molecular-Weight / adverse effects,  pharmacology,  therapeutic use*
Humans
Orthopedic Procedures / adverse effects
Randomized Controlled Trials as Topic
Risk Factors
Venous Thrombosis / drug therapy*,  prevention & control*
Warfarin
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Azetidines; 0/Heparin, Low-Molecular-Weight; 81-81-2/Warfarin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Autonomy, guardianship and mental disorder: one problem, two solutions.
Next Document:  Laparoscopic hand-assisted pancreaticoduodenectomy: initial UK experience.